Solid lipid nanoparticles as a carrier of metformin for transdermal delivery

International Journal of Drug Delivery

Volumn 5, Issue 2, 2013, Pages 137-145

  Sharma, Rakesh Kumar ^a   Sharma, Navneet ^b   Rana, Sudha ^a   Shivkumar, Hosakote G ^b  

^a INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^b JSS COLLEGE OF PHARMACY   (India)

Author keywords

Exvivo studies; Histopathological studies; In vitro In vivo studies; Metformin; Solid lipid nanoparticles; Transdermal patches

Indexed keywords

COBALT 60; METFORMIN; METHYLCELLULOSE; PHOSPHATIDYLCHOLINE; POLYMETHACRYLIC ACID; PROPYLENE GLYCOL; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SCREENING; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; INFLAMMATION; INFRARED SPECTROSCOPY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; RAT; SCANNING ELECTRON MICROSCOPY; TRANSDERMAL PATCH; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84904092276     PISSN: None     EISSN: 09750215     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 414(6865):782-787.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53.
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003; 52(1):102-10.
4. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46.
5. King H, Aubert R. E, Herman W.H. Global burden of diabetes, 1995/2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998; 21:1414-1431
6. Watanabe M, Yamaoka K, Yokotsuka M, Tango T. Randomized controlled trial of a new dietary education program to prevent type 2 diabetes in a high-risk group of Japanese male workers. Diabetes Care. 2003; 26: 3209-3214.
7. Voorham J, Haaijer-Ruskamp FM, Stolk RP. et al. for the Groningen Initiative to Analyze Type 2 Diabetes Treatment Group. Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes. Diabetes Care. 2008; 31:501-503.
8. Harris SB, Kapor J, Lank CN. et al. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician. 2010; 56:e418-e424.
9. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4:203-207.
10. David S, Michael F. Preclinical. Evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. Journal of Controlled Release. 2001;71:107-115.
11. Vidon N, Chaussade S. Metformin in the digestive tract. Diabetes Research and Clinical Practice.1988;4:223-229.
12. Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28(2):187-218.1.
13. Van B R, Gorter K, Stolk R, et al. Clinical inertia in general practice: Widespread and related to the outcome of diabetes care. Fam Pract. 2009; 26:428-436.
14. Ebenezer AN, Terri WJ. Management of type 2 diabetes. Metabolism Clinicall & Experimental.2011; 60:1-23.
15. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur. J. Pharm. Biopharm. 2000; 50: 161-177.
16. Hoffman A, Ziv E. Pharmokinetic considerations of new insulin formulations and routes of administration. ClinPharmacokinet. 1997; 33:285-301.
17. Mugumu H. Transdermal delivery of Caco3-Nanoparticles Containing Insulin. Diabetes Technology & Therapeutics. 2006; 8 (3): 369-374.
18. Michael UA, Yukako Y. Pharmacodynamic-pharmacokinetic profiles of metformin hydrochloride from a mucoadhesive formulation of a polysaccharide with antidiabetic property in streptozotocin-induced diabetic rat models. Biomaterials. 2004; 25: 3041-3048.
19. Yuancai D, Wai KN, Shoucang S, Sanggu K, Reginald BHT. Solid lipid nanoparticles: Continuous and potential large-scale nanoprecipitation production in static mixers. Colloids and Surfaces B: Biointerfaces. 2012; 94: 68-72.
20. Sonali VK, Rajiv VG, Abdul S, Padma VD. Self nano precipitating preconcentrate of tamoxifen citrate for enhanced bioavailability. International Journal of Pharmaceutics. 2012; 429 (1-2): 104-112.
21. Katja J, Wolfgang M, Markus D, Heike B, Christoph J, Karsten M. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. Journal of Controlled Release. 2004; 95 (2, 5):217-227.
22. Guo J, Ping Q, Zhang L. Transdermal delivery of insulin in mice by using lecithin vesicles as a carrier. Drug Deliv. 2000; 7: 113-116.
23. Hoffman A, Ziv E. Pharmokinetic considerations of new insulin formulations and routes of administration. Clin Pharmacokinet. 1997; 33:285-301.
24. Michalowski CB, Guterres SS, Costa TD. Microdialysis for evaluating the entrapment and release of a lipophilic drug from nanoparticles. Journal of Pharmaceutical and Biomedical Analysis. 2004;35:1093-1100.
25. Kim JK, Jeong SP, Chong KK. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. International Journal of Pharmaceutics. 2010; 383(1-2): 209-215.
26. King MJ, Badea I, Solomon J. Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther. 2002; 4: 479-488.
27. Jeffrey EG, Lynlee LL, Rokhaya F, Margaret B. Nanoparticles and microparticles for skin drug delivery. Advanced drug delivery Reviews. 2011;63: 470-491.
28. Pil HL, Robert C, Veerabahu S. Development of an in silico model for human skin permeation based on a Franz cell skin permeability assay. Bioorganic & Medicinal Chemistry Letters. 2010;20: 69-73.
29. Ganeshchandra S, Keishiro T, Akira S, Hiroyuki O, Hiroshi T, Kimiko M. In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size. Colloids and Surfaces B: Biointerfaces. 2008; 65:1-10.
30. Mutalik S, Udupa N. Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide. Journal of Pharmacy and Pharmaceutical Sciences. 2005; 1: 26-38.
31. Kenji S, Yasunori M. Polymers for transdermal drug delivery systems. Journal of Controlled Release. 1994; 29: 177-185